Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2

Status

Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Breast Neoplasms 144Neoplasm Metastasis 16Neoplasms 8Advanced Breast Cancer 8Ovarian Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Breast Cancer Metastatic 5Prostatic Neoplasms 4Endometrial Neoplasms 4Recurrence 3Hereditary Sensory and Autonomic Neuropathies 3Lung Neoplasms 2Hyperglycemia 2Exanthema 2Estrogen Receptor-positive Breast Cancer 2Colorectal Neoplasms 2Carcinoma, Lobular 2Breast Neoplasms, Male 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sex Cord-Gonadal Stromal Tumors 1Sarcoma, Endometrial Stromal 1Salivary Gland Neoplasms 1Recurrent Uterine Corpus Carcinoma 1Neoplastic Cells, Circulating 1

Interventions

Cyclophosphamide 58Dexamethasone 50Rituximab 39Peripheral Blood Stem Cell Transplantation 29Paclitaxel 29Lenalidomide 28fludarabine phosphate 27Gemcitabine 26Etoposide 26Bortezomib 26Cytarabine 25Busulfan 24pembrolizumab 21Radiotherapy 21Bevacizumab 21Carboplatin 20Mycophenolic Acid 19Melphalan 19Cisplatin 19Filgrastim 18pomalidomide 17fludarabine 17Oxaliplatin 17Antilymphocyte Serum 17Cyclosporine 16Tacrolimus 15Methotrexate 15Whole-Body Irradiation 14Methylprednisolone 13Bendamustine Hydrochloride 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Recurrence × Fulvestrant × Clear all
NCT05154487 2026-03-03

A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer

GOG Foundation

Phase 2 Active not recruiting
51 enrolled

Recurrence

NCT06105632 2026-02-13

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Pfizer

Phase 2 Active not recruiting
333 enrolled
Breast

Breast Neoplasms, Recurrence

NCT00334295 2012-07-31

Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.

AstraZeneca

Phase 2 Completed
35 enrolled 9 charts
Gynecologic

Recurrence, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡